1. An immunoregulatory vaccine containing a directed adjuvant containing at least a molecule directed against CD32 connected to a TLR9 ligand and a first peptide alpha helix, and an immunogen with at least one epitope and a second peptide alpha helix twisted with the first alpha -spiral. 2. The vaccine according to claim 1, characterized in that each of the first and second alpha helices contains repeats of an amino acid motif of 3-5 amino acids that specifically bind to each other with a Kd of less than 10 M. A vaccine according to claim 1 or 2, characterized in that said anti-CD32 molecule is selected from the group consisting of an anti-CD32 antibody, an antibody fragment and a peptide. A vaccine according to claim 1 or 2, characterized in that said TLR9 ligand is a TLR9 agonist selected from the group consisting of class A, B and C CpG oligodeoxynucleotides or an immunostimulatory peptide that mimics any of the specified CpG oligodeoxynucleotides. 5. The vaccine according to claim 4, characterized in that said immunogen is obtained on the basis of any of the following: - a tumor specific antigen, for use in immunotherapy of cancer diseases, or - a pathogen, for use in immunotherapy of infectious diseases, or - allergen, for use in immunotherapy allergic diseases. 6. The vaccine according to claim 4, characterized in that said anti-CD32 molecule is directed against CD32a. The vaccine according to claim 4, characterized in that said immunogen is derived from an allergen for use in immunotherapy of allergic diseases, and characterized in that said molecule directed against CD32 is directed against CD32a and CD32b. The vaccine according to claim 1 or 2,1. Иммунорегуляторная вакцина, содержащая- направленный адъювант, содержащий по меньшей мере направленную против CD32 молекулу, соединенную с лигандом TLR9 и первой пептидной альфа-спиралью, и- иммуноген по меньшей мере с одним эпитопом и второй пептидной альфа-спиралью, скрученной с первой альфа-спиралью.2. Вакцина с
